Day One Biopharmaceuticals' Q1'25 sales grew modestly, but Q2 2025 earnings could spark movement. Read why I currently rate ...

BILL Holdings faces macro headwinds & SMB weakness, yet price hikes & strong go-to-market execution hint at future growth.

Discover how Verint Systems' Q1 FY2026 results highlight accelerating AI-driven growth, 8% ARR targets, and tangible AI outcomes transforming the CX space.